{"schema":"sb.node.v1","id":"sb:e/2ec6eb7e97c7c2b7e5b6132e","kind":"entity","label":{"text":"samsung bioepis","locale":"en"},"identity":{"anchor":"label:en:samsung bioepis","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-26T17:45:02.974803+00:00","releaseId":"sb-9a9dbc7280af","snapshot":"deploy c6bbfa09eabb825ccd0b29302e3ab1949d6e0047"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":20,"separatePublishers":7,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"measured","share":0.55,"named":11,"of":20,"basis":"documents whose own title or summary lead names the subject, over every counted document that mentions it anywhere (the entity graph's measurement); receipts are drawn only from rows whose own title or URL names the subject (the entity graph's subject gate)"}},"admission":{"state":"provisional","kind":"observed","kindBasis":"no-vocabulary-row","policy":"promotion (observed tier; not promoted)","reason":"seen recurring in the corpus and kept in the graph at the observation bar; not promoted into the vocabulary"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-09-07","to":"2026-10-25","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0: about 100% of mentions carry no typed assertion"]}},"dimensions":{"domains":["south_korea"],"activeDays":12,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":9,"byKind":{"observation":9},"items":[{"id":"sb:o/4cac8ccff75f243d6077fe2d","kind":"observation","label":"Seoul Economic Daily · 2026-10-25 · Samsung Bioepis Targets 20 Biosimilars by 2030, Eyes ADC and Obesity Drugs","url":"https://en.sedaily.com/culture/2026/10/25/samsung-bioepis-targets-20-biosimilars-by-2030-eyes-adc-and","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/f19c250c650a30417e727f5e","kind":"observation","label":"The korea Herald News · 2026-10-21 · Samsung Bioepis' first ADC candidate wins FDA Fast Track","url":"https://www.koreaherald.com/article/10909967","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/7098819163c2ade612b4c0d9","kind":"observation","label":"Korea Times · 2026-10-21 · Samsung Bioepis wins FDA Fast Track for 1st anticancer drug candidate","url":"https://www.koreatimes.co.kr/business/companies/20261021/samsung-bioepis-wins-fda-fast-track-for-1st-anticancer-drug-candidate?utm_source=rss","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/177b517b97c1d99cda6ad364","kind":"observation","label":"Korea Times · 2026-10-20 · Samsung Bioepis secures 10-year exclusive drug supply deal in Brazil","url":"https://www.koreatimes.co.kr/business/companies/20261020/samsung-bioepis-secures-10-year-exclusive-drug-supply-deal-in-brazil?utm_source=rss","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/0a4589f920b109bd985ef91f","kind":"observation","label":"The korea Herald News · 2026-10-20 · Samsung Bioepis secures 10-year biosimilar supply deal in Brazil","url":"https://www.koreaherald.com/article/10908631","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/929151d91b0b698ebe288e3c","kind":"observation","label":"Seoul Economic Daily · 2026-10-20 · Samsung Bioepis Wins 10-Year Rare Disease Drug Deal in Brazil","url":"https://en.sedaily.com/finance/2026/10/20/samsung-bioepis-wins-10-year-rare-disease-drug-deal-in","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/1f2bba9d9128488016345ed4","kind":"observation","label":"Fierce Pharma · 2026-10-03 · Teva, Samsung Bioepis deepen bonds in pact for up to 6 new biosimilars","url":"https://www.fiercepharma.com/pharma/teva-samsung-bioepis-deepen-bonds-pact-6-new-biosimilars","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/6ead3d60fa6b74b8cef3ec8a","kind":"observation","label":"BioPharma Dive · 2026-10-03 · Lilly, Foghorn part ways; Wave’s FDA-approved plans","url":"https://www.biopharmadive.com/news/foghorn-eli-lilly-wave-samsung-bioepis-teva-varda-hatteras/831918/","match":{"surface":"url","basis":"admitted by the entity graph's subject gate (title or URL); the headline does not name the subject by the door's on-topic test, the URL path does"}},{"id":"sb:o/9b6f84f5c6b3dccaf33a64cd","kind":"observation","label":"Seoul Economic Daily · 2026-10-01 · Samsung Bioepis, Teva Partner on Two Immunology Biosimilars","url":"https://en.sedaily.com/finance/2026/10/01/samsung-bioepis-teva-partner-on-two-immunology-biosimilars","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}}],"cursor":null,"order":"newest first; we keep the 9 newest receipts for this entity whose own title or URL (the entity graph's subject gate) names it; each says which in match. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":2,"byKind":{"claim":2},"items":[{"id":"sb:p/ffc098148aec0d95cb59d275","kind":"claim","label":"Samsung Bioepis secures 10-year exclusive drug supply deal in Brazil — corroborated","role":"named-in","relationKind":"claim","members":0},{"id":"sb:p/b3f1738ac1eaa132f1e2d9df","kind":"claim","label":"Samsung Bioepis wins FDA Fast Track for 1st anticancer drug candidate — reported by two","role":"named-in","relationKind":"claim","members":0}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/2ec6eb7e97c7c2b7e5b6132e","mcp":"traverse {\"id\":\"sb:e/2ec6eb7e97c7c2b7e5b6132e\"}","page":"/entity/samsung-bioepis/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/2ec6eb7e97c7c2b7e5b6132e\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/2ec6eb7e97c7c2b7e5b6132e\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"free-record","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/2ec6eb7e97c7c2b7e5b6132e\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"free-record","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/2ec6eb7e97c7c2b7e5b6132e\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"free-record","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history, which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"free-record","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"free-record","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"watch","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"watch","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"watch","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"watch","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"one-time-read","reason":"one-time Reads are not offered through this door; use ask"}]}